The efficacy of repeated low-level red-light (RLRL) therapy in controlling myopia progression among multi-ethnic children is comparable to, or even better than that identified in Chinese patients in previous trials, a three-month interim study has found.
The Association of Dispensing Opticians of New Zealand (ADONZ) has withdrawn its support for the Australasian College of Optical Dispensing’s (ACOD) Certificate IV in Optical Dispensing, saying it wan…
Assessing the efficacy and safety of RLRL therapy to control myopia progression among multi-ethnic school-aged children, the Australian College of Optometry enrolled a total of 34 myopic children aged 8-13 years. Participants had a cycloplegic spherical equivalent (SE) of -0.50 to -5.00 (inclusive) diopters (D), astigmatism of 2.50D or less, anisometropia of 1.50D or less and monocular best-corrected visual acuity (BCVA) of 20/20 or better.
Participants were randomly assigned to the RLRL group (n=16) or the single-vision spectacles (SVS) group (n=18). RLRL therapy was administered twice daily on weekdays for three-minute sessions, while the SVS group continued routine activities. Assessments were scheduled at baseline and follow-up visits at one, three, six and 12 months, with compliance monitoring and safety assessments throughout. At the three-month follow-up (n=31), the RLRL group demonstrated a significant shortening in AL (-0.07±0.07mm) compared to the SVS group (0.03±0.05mm). Similarly, SE progression experienced a hyperopic shift in the RLRL group (0.26±0.14D) while the SVS group exhibited a myopic shift (-0.03±0.38D). No severe adverse events were reported.
Supported by Eyerising International, the MedRxiv pre-printed study is yet to be peer-reviewed.
Sun Pharma's Cequa (ciclosporin ophthalmic solution, 0.09%) for moderate to severe dry eye is now
A national pathway will enable community optometrists to provide routine four-week post-operative cataract follow-up care for public hospital patients across New Zealand, aiming to improve access and
EssilorLuxottica presented new research at ARVO 2026, including seven-year follow-up data, reinforcing the
New research links glucosamine, a joint pain supplement, to a 25% higher likelihood of progression from mild cognitive impairment (MCI) to